Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Increased demand for pharmaceutical intermediates and APIs, the ramp-up of mass production for newly developed semiconductor-related products and other products, overseas sales, and the review of selling prices contributed to results.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥6,015 million (YoY +3.6%) |
| Operating profit | ¥665 million (YoY +47.0%) |
| Ordinary income | ¥696 million (YoY +38.4%) |
| Profit attributable to owners of the parent | ¥583 million (YoY +25.6%) |
| Total assets | ¥16,252 million |
| Net assets | ¥12,139 million |
| Cash flows from operating activities | ¥563 million |
| Cash flows from investing activities | ¥-266 million |
| Cash flows from financing activities | ¥-115 million |
| Cash and cash equivalents at end of period | ¥4,193 million |
| Revision to Earnings Forecast | Upward revision to the net sales forecast and new disclosure of forecasts for each profit item |
| Segment revenue | Fine Chemicals Business ¥2,940 million (YoY +2.9%), Flame Retardants Business ¥2,357 million (YoY +5.6%), Health Support Business ¥717 million (YoY +0.4%) |
| Segment profit | Fine Chemicals Business ¥775 million (YoY +10.5%), Flame Retardants Business ¥430 million (YoY +79.8%), Health Support Business ¥82 million (YoY +34.0%) |
| Depreciation and amortization | ¥217 million |
| Breakdown of extraordinary income (loss) | Extraordinary income None for the current period (-) / Extraordinary loss Item Loss on disposal of non-current assets / Amount ¥0 million |
| Disclosure regarding the going concern assumption | None |
| Factors Behind Changes in Business Performance | Increased demand for pharmaceutical intermediates and APIs, the ramp-up of mass production for newly developed semiconductor-related products and other products, overseas sales, and the review of selling prices contributed to results. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Increased demand for pharmaceutical intermediates and APIs, the ramp-up of mass production for newly developed semiconductor-related products and other products, and overseas sales contributed to results. In addition, the company expanded transactions with existing customers, secured new projects, reviewed selling prices, and pursued initiatives to ensure profitability.